Wedbush Reiterates Buy Rating on Travere Therapeutics
Wedbush maintains its buy rating on Travere Therapeutics with a $61 target, a 5.74% upside from the current price.
Key Points
- Wedbush reiterated its buy rating on Travere Therapeutics, Inc. (TVTX) with a $61 price target as of June 22, 2026.
- Wedbush's $61 price target implies 5.74% upside from Travere Therapeutics, Inc.'s ($TVTX) current $57.69 share price.
- Shares of Travere Therapeutics traded near $55.15 on Monday, with a market cap of approximately $5.13 billion.
- Insider transactions included both buys and sells on June 12, 2026, while major funds like Janus Henderson and FMR adjusted their positions.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Wedbush has reiterated its buy rating for Travere Therapeutics, Inc. (NasdaqGM: TVTX) with a price target of $61. This update was issued on June 22, 2026, by analyst Laura Chico. On Monday, shares of Travere traded around $55.15.
Wedbush vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in Travere Therapeutics
Several major funds have recently adjusted their holdings in Travere Therapeutics. Janus Henderson Group PLC increased its stake by 908,420 shares, bringing its total to 11,419,586 shares valued at approximately $339.25 million, an 8.6% increase. FMR LLC added 1,350,104 shares, reaching a total of 10,967,967 shares worth about $325.86 million, reflecting a 14% increase. BlackRock, Inc. slightly trimmed its position by 77,319 shares, now holding 7,792,033 shares valued at $231.50 million, a 1% decrease. State Street Corp boosted its holdings by 203,322 shares to a total of 4,959,988 shares, valued at $147.36 million, a 4.3% increase. Meanwhile, Armistice Capital, LLC significantly increased its stake by 1,133,526 shares, now holding 4,897,417 shares worth approximately $145.50 million, marking a 30.1% increase.
Travere Therapeutics, Inc. Stock Down 12.2%
Shares of Travere Therapeutics traded near $55.15 on Monday. The company has a market cap of $5.13 billion, with a forward P/E ratio of 11.36 and a beta of 1.141. Its 52-week low is $13.97, and the high is $55.99. The stock's 50-day moving average is $43.80, while the 200-day moving average is $33.62. Travere has a current ratio of 3.13 and a quick ratio of 2.82, with a debt-to-equity ratio of 331.88.
$TVTX price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Travere Therapeutics reported revenue of $536.20 million, with a growth rate of 55.6%. The company, however, has a negative net margin of -4.0% and a return on equity of -69.4%. The next earnings report is expected on August 6, 2026.
Insider Buying and Selling at Travere Therapeutics, Inc.
On June 12, 2026, insider transactions at Travere Therapeutics included both buying and selling activities. Timothy Coughlin sold 10,000 shares at an average price of $50.07, and Roy Baynes sold 4,500 shares at $50.00 under a planned sale. Conversely, Roy Baynes bought 4,500 shares at an average price of $21.38, and Timothy Coughlin bought 10,000 shares at $26.52.
Analysts Set New Price Targets
On June 22, 2026, Wedbush maintained its buy rating on Travere Therapeutics with a price target of $61. Other analysts have also shown confidence in the stock. Evercore ISI Group maintained its buy rating with a $60 target on June 18, while Citigroup reiterated a buy with a $70 target on June 15. The consensus among analysts is a strong buy, with a mean price target of $57.29 based on 14 opinions.
About Travere Therapeutics
Travere Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for rare kidney and metabolic diseases. Based in San Diego, California, the company is led by CEO Dr. Eric M. Dube. Its product lineup includes FILSPARI, an oral medication targeting IgA Nephropathy, and Thiola for cystinuria. Travere's pipeline features Sparsentan and Pegtibatinase, both aimed at treating rare conditions.
Bottom Line
Wedbush's reaffirmation of a buy rating with a $61 target shows continued confidence in Travere Therapeutics. Investors keep an eye on analyst updates and institutional movements as they gauge the company's potential. Remember, 13F filings and analyst reports are backward-looking and may not reflect current positions or opinions.
Get Travere Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $TVTX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.